長庚大學

經歷

學會與認證

研究計畫

論文發表

• Liu TT, You HL, Weng SW, Wei YC, Eng HL, Huang WT*. Recurrent Amplification at 13q34 Targets at CUL4A, IRS2, and TFDP1 As an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma. PLoS One. 2015 Dec 18;10(12) (SCI; IF=3.240; Multidisciplinary sciences 26/72) (Co-first author)
• Liu TT, Weng SW, Wang MC, Huang WT*. Nontuberculous mycobacterial infection with concurrent IgG4-related lymphadenopathy. APMIS 2016 Mar 14;124(3):216-20. (SCI; IF= 3.205; Pathology 35/77)
• Tsao CF, Huang WT, Liu TT, Wang PW, Liou CW, Ling TK, Hsien CJ, Weng SW*. Expression of high-mobility group box protein 1 in diabetic foot atherogenesis. Genet Mol Res 2015; 14 (2): 4521-4531. (Non-SCI)
• Li CF, Chuang IC, Liu TT, Chen KC, Chen YY, Fang FM, Li SH, Chen TJ, Yu SC, Lan J, Huang HY*. Transcriptomic reappraisal identifies MGLL overexpression as an unfavorable prognosticator in primary gastrointestinal stromal tumors. Oncotarget. 2016, 7(31):49986-49997. (Non-SCI)
• Chiang WY, Liu TT, Huang WT, Kuo MT*. Co-existing ligneous conjunctivitis and IGG4-related disease. Indian J Ophthalmology 2016 Jul; 64:532-534. (SCI; IF= 1.848; Ophthalmology 48/62)
• Li CF, Liu TT, Chuang IC, Chen YY, Fu-Min Fang FM, Chan TC, Li WS, Huang HY*. PLCB4 copy gain and PLCß4 overexpression in primary gastrointestinal stromal tumors: integrative characterization of a lipid-catabolizing enzyme associated with worse disease-free survival. Oncotarget. 2017 Mar 21;8(12):19997-20010. (Non-SCI)
• Wang SC, Wu YT, Liu TT, Weng SW, You HL, Wei YC, Eng HL, Huang WT*. Amplification and overexpression of the met gene in intrahepatic cholangiocarcinoma correlate with adverse pathological features and worse clinical outcome. Intern J Clin Exper Pathol 2017 Jun; 10:6809-6817. (Non-SCI)
• Li CF, Fang FM, Chen YY, Liu TT, Chan TC, Yu SC, Chen LC, Huang HY*. Overexpressed fatty acid synthase in gastrointestinal stromal tumors: targeting a progression-associated metabolic driver enhances the antitumor effect of imatinib. Clin Cancer Resear 2017 Aug; 23:4908-4918. (SCI; IF= 12.531; Oncology 18/242)
• Huang GK, Liu TT, Weng SW, You HL, Wei YC, Chen CH, Eng HL, Huang WT*. CUL4A Overexpression as an Independent Adverse Prognosticator in Intrahepatic Cholangiocarcinoma. BMC Cancer (2017) 17:395 DOI 10.1186/s12885-017-3389-z (SCI; IF= 4.430; Oncology 110/242) (Co-first author)
• You HL, Huang WT*, Liu TT, Weng SW, Eng HL. Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma. Exp Mol Pathol. 2017 Dec;103(3):249-254 (SCI; IF= 3.362; Pathology 31/77)
• You HL, Liu TT, Weng SW, Chen CH, Wei YC, Eng HL, Huang WT*. Association of IRS2 overexpression with disease progression in intrahepatic cholangiocarcinoma. Oncol Lett. 2018 Oct;16(4):5505-5511. (SCI; IF= 2.967; Oncology 185/242) (Co-first author)
• Huang HS, Liao CK, Liu TT, You HL, Wang MC, Huang WT*. TP53 mutations in peripheral mature T and NK cell lymphomas: a whole-exome sequencing study with correlation to p53 expression. Hum Pathol. 2018 Oct;80:145-151. (SCI; IF= 3.466; Pathology 27/77)
• Li CF, Liu TT, Wang JC, Yu SC, Chen YY, Fang FM, Li Ws, Huang HY*. Hydroxysteroid 11-b dehydrogenase 1 overexpression with copy-number gain and missense mutations in primary gastrointestinal stromal tumors. J Clin Med. 2018 Nov 1;7(11). pii: E408. doi: 10.3390/jcm7110408  (SCI, IF=4.242; Medicine, General & internal 39/167) (co-first author)
• Wu CN, Liu TT, Yang CH, Hwang CF*. Current and future treatments for external auditory canal cancer. International Journal of Head and Neck Science 2019, 3(2): 78-91. (Non-SCI)
• Lee PH, Weng SW, Liu TT, Yu HL, Wang MC*, Huang WT*. RHOA G17V mutation in angioimmunoblastic T-cell lymphoma: A potential biomarker for cytological assessment. Exp Mol Pathol 2019 Oct;110:104294. (SCI; IF= 3.362; Pathology 31/77)
• Tsai MC, Huang CC, Wei YC, Liu TT, Lin MT, Yi LN, Lin PR, Wang CC, Chu TH, Hsiao CC, Hu TH*, Tai MH*. Combined Chibby and β-Catenin Predicts Clinical Outcomes in Patients with Hepatocellular Carcinoma. Int J Mol Sci 2019, 21, 2060. (SCI; IF= 5.924; Biochemistry & molecular biology 67/295)
• Su YL*, Luo HL, Huang CC, Liu TT, Huang EY, Sung MT, Lin JJ, Po‐Hui Chiang PH, Chen YT, Kang CH, Cheng YT. Galectin‐1 Overexpression Activates the FAK/PI3K/AKT/mTOR Pathway and Is Correlated with Upper Urinary Urothelial Carcinoma Progression and Survival. Cells 2020, 9, 806. (SCI; IF= 6.600; Cell biology 53/195)
• Kuo MC, Su PJ, Huang CC, Luo HL, Chiu TJ, Li SH, Wu CC, Liu TT, Cheng YT, Kang CH, Su YL*. Safety and efficacy of immune checkpoint inhibitors for patients with metastatic urothelial carcinoma and end-stage renal disease: experiences from real-world practice. Frontiers in Oncol 2020, 10: 58483. (SCI; IF= 6.244; Oncology 62/242)
• Weng SW, Liu TT, Eng, HL, You HL, Huang WT*. Autophagy plays a role in the CUL4A-related poor prognosis of intrahepatic cholangiocarcinoma. Pathol Oncol Res 2021 Feb; https://doi.org/10.3389/pore.2021.602714 . (SCI; IF= 3.201; Pathology 36/77)
• Hu WH, Yang WH, Liu PF, Liu TT, Morgan P, Tsai WL, Pan HW, Lee CH, Shu CW*. Clinicopathological association of autophagy related 5 protein with prognosis of colorectal cancer. Diagnostics 2021, 11: 782.(SCI, IF=3.706; Medicine, General & internal 45/167)
• Hu WH, Chang CD, Liu TT, Chen HH, Hsiao CC, Kang HY, Chuang JH*. Association of sarcopenia and expression of interleukin-23 in colorectal cancer survival. Clin Nutrit 2021, 40: 5322-5326(SCI, IF=7.325; Nutrition& Dietetics 7/88)
• Wang CC, Huang KT, Chang HC, Tseng CC, Lai CH, Lan J, Liu TT, Huang CC*, Lin MC. Comprehensive analysis of PD-L1 in non-small cell lung cancer with emphasis on survival benefit, impact of driver mutation and histological types, and archival tissue. Thorac Cancer. 2022 Jan;13:38–47. (SCI, IF=3.5; Respiratory system 26/64)
• Lee PH, Kao YC, Hsieh TH, Liao JB, Li CF, Lee CH, Chang YM, Chang CD, Huang SC, Chen TJ, Liu TT, Yu SC, Huang HY*. Myoepithelial and oral intracranial myxoid mesenchymal tumor-like neoplasms as diagnostic considerations of the ever-expanding extracranial myxocollagenous tumors harboring FET-CREB fusions. Pathol Res Pract 2022 Jan;229:153700. (SCI, IF=3.25; Pathology 33/77)
• Lin SH, Eng HL, Liu YW, Lin CC, Yong CC, Wang CC, Chen CL, Kuo FY, Chen YF, Wang JH, Yen YH, Liu TT, Li WF, Cheng CH*. Characteristics and prognosis of patients with large well-differentiated hepatocellular carcinoma who have undergone resection. Am J Surg. 2022 Feb;223(2):339-345. (SCI, IF=2.565; Surgery 99/211)
• Lee PH, Huang SC, Wu PS, Tai HC, Lee CH, Lee JC, Kao YC, Tsai JW, Hsieh TH, Li CF, Li WS, Liu TT, Su YL, Yu SC, Huang HY*. Molecular Characterization of Dermatofibrosarcoma Protuberans The Clinicopathologic Significance of Uncommon Fusion Gene Rearrangements and Their Diagnostic Importance in the Exclusively Subcutaneous and Circumscribed Lesions. Am J Surg Pathol. 2022 Jan 17. (SCI, IF=6.394; Pathology 9/77)
•  Liu TT, Li CF, Tan KT, Jan YH, Lee PH, Huang CH, Yu SC, Tsao CF, Wang JC and Huang HY*. Characterization of Aberrations in DNA Damage Repair Pathways in Gastrointestinal Stromal Tumors: The Clinicopathologic Relevance of γH2AX and 53BP1 in Correlation with Heterozygous Deletions of CHEK2, BRCA2, and RB1. Cancers 2022 Mar 31;14(7):1787. (SCI; IF= 6.639; Oncology 51/242)
• Liu TT, Hu WH, Liu PF, Morgan P, Lin IL, Tsai WL, Cheng YY, Hsieh AT, Hu TH, Chu CW*. ATG4B and pS383/392-ATG4B serve as potential biomarkers and therapeutic targets of colorectal cancer. Cancer Cell Int. 2023 23:63. (SCI; IF= 5.8; Oncology 25/223)
• Huang SC , Chang Ian YF, Chang CJ, Liu H, Chen KH, Liu TT, Hsieh TY, Chuang HC, Chen CC, Lin IC, Ng KF, Huang HY* and Chen TC*. Association between hepatic angiosarcoma and end-stage renal disease: nationwide population-based evidence and enriched mutational signature of aristolochic acid exposure. J Pathol June 2023; 260: 165–176.
• Liu YY, Tsai MY, Liu TT, Liu YW, Lin YH, Yeh CH, Lin YC, Chen YH. The real-world efficacy and safety of nivolumab plus chemotherapy in patients with HER2-negative advanced gastric cancer. BMC Cancer (2024) 24:1325.